NOVARTIS

Ilaris - resources for patients - HCP

[Prescribing information]

Image

Image

Resources for HCPs to give patients

Indications[1]

Periodic fever syndromes
ILARIS is indicated for the treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents and children aged 2 years and older:

- Cryopyrin-associated periodic syndromes (CAPS), including:
  - Muckle-Wells syndrome (MWS)

    - Neonatal-onset multisystem inflammatory disease (NOMID)/chronic infantile neurological, cutaneous, articular syndrome (CINCA)

    - Severe forms of familial cold autoinflammatory syndrome (FCAS)/familial cold urticaria (FCU) presenting with signs and symptoms beyond cold-induced urticarial skin rash

- Tumour necrosis factor receptor associated periodic syndrome (TRAPS)

- Hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD)

- Familial Mediterranean Fever (FMF)

    - ILARIS should be given in combination with colchicine, if appropriate

Still’s disease
ILARIS is indicated in patients who have responded inadequately to previous therapy with non-steroidal anti-inflammatory drugs (NSAIDs) and systemic corticosteroids, for the treatment of active Still’s disease, including:

- Adult-onset Still’s disease (AOSD)

- Systemic juvenile idiopathic arthritis (SJIA) in patients aged 2 years and older

- ILARIS can be given as monotherapy or in combination with methotrexate

Gouty arthritis
ILARIS is indicated for the symptomatic treatment of adult patients with frequent gouty arthritis attacks (at least 3 attacks in the previous 12 months) in whom non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine are contraindicated, are not tolerated, or do not provide an adequate response, and in whom repeated courses of corticosteroids are not appropriate.

Resources for HCPs to share with patients who have been prescribed ILARIS® (canakinumab) to treat their periodic fever syndrome or Still’s disease.

Please do not show this webpage to patients, or direct them to this webpage. Instead, please direct patients to the patient portal.

Patient guide to ILARIS® treatment

A booklet about what ILARIS is, how it works, and things to know before starting treatment.

Image

A GUIDE TO YOUR ILARIS® (CANAKINUMAB) TREATMENT

ILARIS®
(canakinumab)
150 mg subcutaneous injection

Funded and developed by Novartis Pharmaceuticals UK Ltd.
This booklet is intended for patients or caregivers of patients who have been prescribed Ilaris for their periodic fever syndrome.

This document does not replace the patient information leaflet that accompanies your medication

NOVARTIS

Patient guide – English

PDF
Download
Image

ILARIS®
(canakinumab)
150 mg subcutaneous injection

دليل عن علاج Ilaris®
(كاناكينوماب)

NOVARTIS

يمويل وتطوير من شركة Novartis Pharmaceuticals UK Ltd.

هذا الكتيب موجه للمرضى أو مقدمي الرعاية للمرضى الذين تم وصف Ilaris لعلاج متلازمة الحمى الدورية لديهم.
لا يحل هذا المستند محل نشرة معلومات المريض المصاحبة لأدويتك

Patient guide – Arabic

PDF
Download
Image

ILARİS® (CANAKİNUMAB) TEDAVİNİZ İÇİN REHBER

ILARIS
(canakinumab)
150 mg subcutaneous injection

Novartis Pharmaceuticals UK Ltd. tarafından finanse edilmiş ve hazırlanmıştır. Bu kitapçık, periyodik ateş sendromu için Ilaris reçete edilen hastalara veya bu hastaların bakıcılarına yönelik olarak tasarlanmıştır.

Bu doküman, ilacınızla birlikte verilen hasta bilgilendirme broşürünün yerini almaz.

NOVARTIS

Patient guide – Turkish

PDF
Download

CAPS, cryopyrin-associated periodic syndromes; FMF, familial Mediterranean fever; HCP, healthcare professional; HIDS, hyperimmunoglobulin D syndrome; MKD, mevalonate kinase deficiency; TRAPS, tumour necrosis factor receptor-associated periodic syndrome.

Reference

1. ILARIS® (canakinumab) Summary of Product Characteristics.

Safety profile in PFS

Safety profile in PFS

See more details

Hide details

UK | March 2025 | FA-11307389

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email medinfo.uk@novartis.com or call 01276 698370.
